Correlation Between NYSE Composite and Inhibikase Therapeutics
Can any of the company-specific risk be diversified away by investing in both NYSE Composite and Inhibikase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NYSE Composite and Inhibikase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between NYSE Composite and Inhibikase Therapeutics, you can compare the effects of market volatilities on NYSE Composite and Inhibikase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NYSE Composite with a short position of Inhibikase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of NYSE Composite and Inhibikase Therapeutics.
Diversification Opportunities for NYSE Composite and Inhibikase Therapeutics
-0.33 | Correlation Coefficient |
Very good diversification
The 3 months correlation between NYSE and Inhibikase is -0.33. Overlapping area represents the amount of risk that can be diversified away by holding NYSE Composite and Inhibikase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibikase Therapeutics and NYSE Composite is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NYSE Composite are associated (or correlated) with Inhibikase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibikase Therapeutics has no effect on the direction of NYSE Composite i.e., NYSE Composite and Inhibikase Therapeutics go up and down completely randomly.
Pair Corralation between NYSE Composite and Inhibikase Therapeutics
Assuming the 90 days trading horizon NYSE Composite is expected to generate 0.17 times more return on investment than Inhibikase Therapeutics. However, NYSE Composite is 5.93 times less risky than Inhibikase Therapeutics. It trades about 0.27 of its potential returns per unit of risk. Inhibikase Therapeutics is currently generating about -0.18 per unit of risk. If you would invest 1,895,821 in NYSE Composite on October 20, 2024 and sell it today you would earn a total of 64,916 from holding NYSE Composite or generate 3.42% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
NYSE Composite vs. Inhibikase Therapeutics
Performance |
| Timeline |
NYSE Composite and Inhibikase Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
NYSE Composite
Pair trading matchups for NYSE Composite
Inhibikase Therapeutics
Pair trading matchups for Inhibikase Therapeutics
Pair Trading with NYSE Composite and Inhibikase Therapeutics
The main advantage of trading using opposite NYSE Composite and Inhibikase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NYSE Composite position performs unexpectedly, Inhibikase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will offset losses from the drop in Inhibikase Therapeutics' long position.| NYSE Composite vs. National Health Investors | NYSE Composite vs. Arbor Realty Trust | NYSE Composite vs. Canaf Investments | NYSE Composite vs. Freedom Holding Corp |
| Inhibikase Therapeutics vs. DiaMedica Therapeutics | Inhibikase Therapeutics vs. Milestone Pharmaceuticals | Inhibikase Therapeutics vs. Seres Therapeutics | Inhibikase Therapeutics vs. Oncolytics Biotech |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Complementary Tools
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |